TME Pharma N.V.
ALTME.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.74M
Close$
$-0.00
103.8% downside
Current Fair Value
103.8% downsideOvervalued by 103.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.74 Million |
|---|---|
| Enterprise Value | $11.11 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.03 |
| Beta | 0.61 |
| Outstanding Shares | 94,150,719 |
Return
| Return on Equity | 570.42% |
|---|---|
| Return on Assets | -421.08% |
| Return on Invested Capital | 516.40% |
Valuation & Multiples
| P/E Ratio | -3.27 |
|---|---|
| PEG | 6.26 |
| Price to Sales | - |
| Price to Book Ratio | -0.11 |
| Enterprise Value to Revenue | 584.92 |
| Enterprise Value to EBIT | -1.36 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | -1.51 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About TME Pharma N.V.
12 employees
CEO: Diede van den Ouden TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to adva...